Listen in the Podli app 🎧
Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Featuring perspectives from Dr Alexandra Drakaki, including the following topics:
- Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00)
- Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointestinal toxicity — Part 2 (5:37)
- Case: A man in his early 50s with metastatic bladder cancer receives second-line EV monotherapy intermittently (15:09)
- Case: A woman in her mid 60s with bladder cancer and a history of rheumatoid arthritis develops oligometastatic progression in the lung and receives EV monotherapy (21:03)
- Case: A man in his mid 80s with HER2-positive (IHC 3+) metastatic bladder cancer receives trastuzumab deruxtecan and develops ground glass opacities in his lungs concerning for pneumonitis (30:43)
CME information and select publications
